The Phillippines released official guidance on companies filing for EUAs in regards to COVID. Those guidelines stated that drug in question should have an EUA from a their country (or interpreted as an EUA from a legitimate country) beige applying for EUA in the Phillippines. That would indicate that leronlimab requires an EUA from the U.S., U.K., or Canada before applying for an EUA in the Philippines. CYDY is working with Chiral(?) pharmaceuticals so it’s possible that Chiral has gotten the go ahead from the Filipino FDA to apply without a previous EUA. We’ll find out soon enough.